Stock Update (NASDAQ:ETRM): EnteroMedics Inc’s vBloc® Neurometabolic Therapy Featured on “The Doctors” TV Show


EnteroMedics Inc (NASDAQ:ETRM) announced that its vBloc®Neurometabolic Therapy for the treatment of obesity will be featured on the March 14 episode of the Emmy Award-winning syndicated daytime talk show The Doctors. Frank Chae, MD, FACS, Chief Surgeon and Head of the Bariatric Center at Sky Ridge Medical Center in Colorado and Cindy Hudak, one of his patients who received vBloc Therapy will discuss the benefits of vBloc Therapy and Cindy’s personal story of battling obesity. The Doctors, on air since 2008, offers the most timely, topical and practical health, wellness and lifestyle information on daytime television.

The Doctors is a well-respected television show many people watch in order to learn about different medical conditions, including obesity, and the latest innovative treatments available to them,” said Dan Gladney, EnteroMedics President, Chief Executive Officer and Chairman of the Board. “We are thrilled The Doctors has decided to feature vBloc Therapy and hope patients who see the segment and are appropriate for its use will take action and contact their doctor to learn more about its benefits. I also want to applaud vBloc patient Cindy Hudak for her great success to date and thank her for sharing her story.”

vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.

Shares of Enteromedics jumped over 20% t0 $7.33 in after-hours trading Monday. ETRM has a 1-year high of $86.80 and a 1-year low of $1.75. The stock’s 50-day moving average is $6.94 and its 200-day moving average is $2.83.

EnteroMedics, Inc. is a clinical development stage medical device company that engages in the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. Its initial product Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts